Jun 5, 2026
In this episode, we explore when and why long-acting injectable antipsychotics (LAIs) should be considered for patients with schizophrenia, covering approved indications, ideal candidate profiles, and the critical role of shared decision-making in treatment planning.
Faculty: Brian Miller, M.D., Ph.D., M.P.H.
Host: Richard Seeber, M.D.